ArticleEuropean journal of nuclear medicine and molecular imaging2018
Prognostic role of serial quantitative evaluation of
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review.Journal of the American Heart Association · 2021Pooled it
- Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Pooled it
- Strict carbohydrate restriction enables volume-based FDG-PET/CT to outperform SUVmax for risk stratification in cardiac sarcoidosis.International journal of cardiology. Heart & vasculature · 2026Article
- The Role of Multimodality Imaging in Guiding Ventricular Tachycardia Ablation: An Updated Review.Reviews in cardiovascular medicine · 2026Review
- Article
- Cardiac Sarcoidosis: Pathophysiology and Diagnostic-Therapeutic Processes.Reviews in cardiovascular medicine · 2026Review
- Myocardial-to-background ratio in F18-fluorodeoxyglucose PET in cardiac sarcoidosis for diagnosis and evaluation of therapeutic response.International journal of cardiology. Heart & vasculature · 2025Article
- Innovations in Imaging:Current cardiology reports · 2024Review
- Cardiac Sarcoidosis: Utilizing Cardiac MRI and PET-CT.Current cardiology reports · 2024Review
- Clinical Applications of Cardiac Magnetic Resonance Parametric Mapping.Diagnostics (Basel, Switzerland) · 2024Review
- Machine learning approach usingJapanese journal of radiology · 2024Article
- Sarcoid heart disease and imaging.Heart rhythm O2 · 2024Review
- Editorial: Immune-mediated damage to the heart and lungs in autoimmune diseases.Frontiers in immunology · 2024Article
- Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases.European heart journal · 2023Review
- Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- FDG uptake patterns in isolated and systemic cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Cardiac sarcoidosis: the role of cardiac MRI andThe British journal of cardiology · 2023Article
- Potential novel imaging targets of inflammation in cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Review
- Controversies in the Treatment of Cardiac Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Article
- PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPositron emission tomography (PET) with
objectivesWe sought to investigate the clinical impact of serial quantitative FDG uptake analysis in patients with CS presenting with ventricular tachycardia (VT) treated by catheter ablation (CA).
methodsWe followed 20 patients (51 ± 9 years, 70% males) with CS and VT who underwent CA, with 92 serial FDG-PET scans (3-10 per patient). Myocardial FDG-avid lesions were quantified using three parameters: maximum standardized uptake value (SUV
resultsDuring a median follow-up of 35 (20-66) months, 18 MACE (1 death, 2 heart transplants, 12 ICD appropriate interventions, 3 hospitalizations) occurred in 12 (60%) patients. At univariable analysis, lack of PET improvement (defined by decrease in LMA of at least 25%) was the only variable associated with cardiac events during follow-up. In particular, non-responders had a 20-fold higher risk of MACE at follow-up (HR 18.96, 95% CI 2.26-159.27; p = 0.007). Moreover, a significant linear inverse relationship was observed between changes in LMA and changes in left ventricular ejection fraction over follow-up (β = -20.11; p = 0.003).
conclusionsIn patients with CS and VT, temporal change in FDG uptake evaluated by a quantitative approach is associated with parallel change in systolic function. Moreover, reduction in FDG uptake is strongly associated with fewer MACE at long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.